ELZONRIS

This brand name is authorized in Estonia, Croatia, Ireland, Lithuania, Poland, United States

Active ingredients

The drug ELZONRIS contains one active pharmaceutical ingredient (API):

1 Tagraxofusp UNII 8ZHS5657EH - TAGRAXOFUSP

Tagraxofusp is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Read about Tagraxofusp

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ELZONRIS Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01XX67		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX67

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1836479
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091753
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100446916
Country: US	FDA, National Drug Code	Identifier(s): 72187-0401